The Royal Wolverhampton NHS Trust   Report issue

Academic/Hospital Phase 4
Founded: Wolverhampton United Kingdom (1994)

Organization Overview

First Clinical Trial
2015
NCT02376283
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

The Royal Wolverhampton Hospitals NHS Trust | The Royal Wolverhampton NHS Trust

Active Ingredients

Drugs in Phase 4 Trials (4)

cangrelor (kengreal) (1 trial)

clopidogrel (plavix) (1 trial)

prasugrel (effient) (1 trial)

ticagrelor (brilinta) (2 trials)

Drugs in Other Trials (1)

licorice (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Angina, Unstable (Phase 4)

Infarction (Phase 4)

Myocardial Infarction (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 5